CPAI
Counterpoint Quantitative Equity ETF
Counterpoint Quantitative Equity ETF seeks to provide long-term capital appreciation by investing in a diversified portfolio of U.S. equities identified through a systematic quantitative investment process.
US
EQUITY
Active
MANAGEMENT STYLE
$ 342.4 M
ASSETS UNDER MGMT
75 bp
EXPENSES
Fund Basics
| Inception date | Nov 28, 2023 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| A-MARK PRECIOUS METALS, INC. | 1,000.0 % |
| ASTERA LABS INC | 79.7 % |
| MICRON TECHNOLOGY INC | 71.0 % |
| CREDO TECHNOLOGY GROUP HOLDING LTD. | 61.6 % |
| CENTENE CORP | 39.4 % |
| AMN HEALTHCARE SERVICES INC | 35.8 % |
| TENABLE HOLDINGS, INC. | 33.7 % |
| LIGHTPATH TECHNOLOGIES INC-A | 32.0 % |
| TERADYNE INC | 31.3 % |
| VIAVI SOLUTIONS INC. | 30.0 % |
Constituent Breakdown
| Number of holdings | 51 |
| Herfindahl-Hirschman Index | 23,756 |
| Wgt avg mkt cap (mns) | $1,156,767 |
| Large cap (>$10bn) | 606.9% |
| Mid cap ($2-10bn) | 349.9% |
| Small cap (<$2bn) | 1,170.5% |
| Developed mkts. | 1,108.6% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 1,000.0 % |
 |
GREECE | 23.9 % |
 |
LUXEMBOURG | 23.9 % |
 |
CANADA | 22.7 % |
 |
ISRAEL | 22.0 % |
 |
BERMUDA | 16.1 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 27.5% | 46.7% | 27.3% | -- | -- | -- | -- | 32.7% |
| Dividend Yield | 0.0% | 0.0% | 0.2% | -- | -- | -- | -- | 0.2% |
| Total Returns | 27.5% | 46.7% | 27.6% | -- | -- | -- | -- | 33.0% | Ann. Volatility | 21.8% | 18.2% | 20.3% | -- | -- | -- | -- | 19.1% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.16 | 57% |
| MSCI EAFE | 0.78 | 41% |
| MSCI Emg Mkts | 0.60 | 43% |
Liquidity Measures
| Avg. volume (000) | 84 |
| ADV traded (mns) | $4 |
| Turnover | 1.3% |
| Avg. Bid/Ask (% of price) | 0.17% |
Technical Indicators
| 30d moving avg. (EMA) | $49.73 |
| Relative strength (RSI) | 58 |
| MACD/Signal | 0.62/0.75 |
| Bollinger Bands (Upper/Lower) | $52.26/$49.03 |
| Short interest (% of AUM) | 0.2% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. CPAI |
Expenses vs. CPAI |
ALTAR Score™ vs. CPAI |
|---|---|---|---|---|
| SSCP | SMART Small Cap ETF | 328.7% | +4 bp | -1.4% |
| TCV | Towle Value ETF | 226.3% | +10 bp | +2.4% |
| CVY | Invesco Zacks Multi-Asset Income ETF | 39.2% | +31 bp | +5.6% |
| IHE | iShares U.S. Pharmaceuticals ETF | 35.2% | -35 bp | -0.4% |
| SVAL | iShares US Small Cap Value Factor ETF | 30.7% | -55 bp | +1.9% |
| PPH | VanEck Pharmaceutical ETF | 30.2% | -39 bp | +2.2% |
| VLUE | iShares MSCI USA Value Factor ETF | 30.0% | -60 bp | +1.1% |
| IGPT | Invesco AI and Next Gen Software ETF | 24.8% | -15 bp | -2.5% |
| WAR | U.S. Global Tech and Aerospace & Defense ETF | 24.5% | -15 bp | -4.9% |
| JIVE | JPMorgan International Value ETF | 23.9% | -20 bp | +3.7% |
Risk and Returns: CPAI vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 6/30/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
5.4%
ALTAR SCORE™
52nd
PERCENTILE
NEUTRAL
ETFRC RATING
There are 1,398 funds in the US Equity category with an average
ALTAR Score™ of 5.3% and a standard deviation
of 2.1%. CPAI's ALTAR Score™ is approximately 0.0 standard
deviations above the category average. This places CPAI in the 52nd percentile
among funds in the category.
Sell-Side Consensus
$63.82
PRICE TARGET
+24.1%
UPSIDE